


## WHAT IS CLAIMED IS:


1. A compound of formula (I) and pharmaceutically acceptable salts thereof



wherein

Y is CH or N;

R<sup>1</sup> is



R<sup>2a</sup> is selected from (1) a group selected from R<sup>a</sup>, (2) (CH<sub>2</sub>)<sub>n</sub>NR<sup>b</sup>C(O)R<sup>a</sup>, (3) (CH<sub>2</sub>)<sub>n</sub>NR<sup>b</sup>SO<sub>2</sub>R<sup>d</sup>, (4) (CH<sub>2</sub>)<sub>n</sub>NR<sup>b</sup>CO<sub>2</sub>R<sup>a</sup>, (5) (CH<sub>2</sub>)<sub>k</sub>-heterocycle optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, OR<sup>a</sup>, SR<sup>a</sup>, C<sub>1-4</sub> alkyl and C<sub>1-3</sub> haloalkyl wherein said heterocycle is (a) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms wherein said ring is optionally benzo-fused; or (b) a 6-membered heteroaromatic ring containing from 1 to 3 ring nitrogen atoms and N-oxides thereof, wherein said ring is optionally benzo-fused, (6) (CH<sub>2</sub>)<sub>k</sub>CO<sub>2</sub>R<sup>a</sup>, and (7) (CH<sub>2</sub>)<sub>k</sub>C(O)NR<sup>b</sup>R<sup>c</sup>,

R<sup>2b</sup> is OH or a group selected from R<sup>2a</sup>; or

R<sup>2a</sup> and R<sup>2b</sup> together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted with 1 to 4 groups independently selected from halogen, OR<sup>a</sup>, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> haloalkyl;

R<sup>3a</sup> and R<sup>3b</sup> are independently selected from hydrogen, C<sub>1-4</sub> alkyl, and C<sub>1-4</sub> haloalkyl;


R<sup>4a</sup> and R<sup>4b</sup> are independently selected from hydrogen and halogen;

R<sup>6</sup> is selected from (1) C<sub>1-8</sub> alkyl optionally substituted with 1-5 groups independently selected from halogen, nitro, cyano, COR<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, C(O)NR<sup>b</sup>R<sup>c</sup>, OR<sup>a</sup>, OC(O)R<sup>a</sup>, SR<sup>a</sup>, SO<sub>2</sub>R<sup>d</sup>, S(O)R<sup>d</sup>, NR<sup>b</sup>R<sup>c</sup>,

- NR<sup>b</sup>C(O)R<sup>a</sup>, NR<sup>b</sup>SO<sub>2</sub>R<sup>d</sup>, and NR<sup>b</sup>CO<sub>2</sub>R<sup>a</sup>, (2) C<sub>3-8</sub> cycloalkyl, (3) C<sub>2-8</sub> alkenyl optionally substituted with CO<sub>2</sub>R<sup>a</sup>, (4) halogen, (5) cyano, (6) nitro, (7) NR<sup>b</sup>R<sup>c</sup>, (8) NR<sup>b</sup>C(O)R<sup>a</sup>, (9) NR<sup>b</sup>CO<sub>2</sub>R<sup>a</sup>, (10) NR<sup>b</sup>C(O)NR<sup>b</sup>R<sup>c</sup>, (11) NR<sup>b</sup>C(O)NR<sup>b</sup>CO<sub>2</sub>R<sup>a</sup>, (12) NR<sup>b</sup>SO<sub>2</sub>R<sup>d</sup>, (13) CO<sub>2</sub>R<sup>a</sup>, (14) COR<sup>a</sup>, (15) C(O)NR<sup>b</sup>R<sup>c</sup>, (16) C(O)NHO<sup>a</sup>, (17) C(=NOR<sup>a</sup>)R<sup>a</sup>, (18) C(=NOR<sup>a</sup>)NR<sup>b</sup>R<sup>c</sup>, (19) OR<sup>a</sup>, (20) OC(O)R<sup>a</sup>, (21) S(O)<sub>v</sub>R<sup>d</sup>, (22) SO<sub>2</sub>NR<sup>b</sup>R<sup>c</sup>, (23) optionally substituted heterocycle where the heterocycle is (a) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, (b) a 6-membered heteroaromatic ring having 1 to 3 ring N atoms, (c) 4,5-dihydro-oxazolyl or (d) 4,5-dihydro-1,2,4-oxadiazolyl, and wherein said substituent is 1 to 3 groups independently selected from C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 halogen atoms, OR<sup>a</sup> or OC(O)R<sup>a</sup>, (24) phenyl optionally substituted with 1 to 3 groups independently selected from halogen, nitro, cyano, OR<sup>a</sup>, SR<sup>a</sup>, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> haloalkyl, and (25) OSO<sub>2</sub>R<sup>d</sup>;
- R<sup>7</sup> is selected from hydrogen and halogen;
- R<sup>8</sup> and R<sup>9</sup> are independently selected from hydrogen and a group from R<sup>6</sup>; with the proviso that not more than one of R<sup>6</sup>, R<sup>8</sup>, and R<sup>9</sup> is a heterocycle;
- R<sup>a</sup> is selected from (1) hydrogen, (2) C<sub>1-7</sub> alkyl optionally substituted with 1 to 5 halogen atoms, OH, SH, O-C<sub>1-4</sub>alkyl, or S-C<sub>1-4</sub>alkyl, (3) (CH<sub>2</sub>)<sub>k</sub>-phenyl optionally substituted with 1 to 3 groups independently selected from halogen, cyano, nitro, OH, C<sub>1-4</sub> alkyloxy, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> alkyl and C<sub>1-4</sub>haloalkyl, and (4) C<sub>3-6</sub> cycloalkyl;
- R<sup>b</sup> and R<sup>c</sup> are independently selected from (1) hydrogen, (2) C<sub>1-4</sub> alkyl optionally substituted with 1 to 5 groups independently selected from halogen, amino, CO<sub>2</sub>R<sup>a</sup>, OR<sup>a</sup>, mono-C<sub>1-4</sub>alkylamino, and di-C<sub>1-4</sub>alkylamino, (3) (CH<sub>2</sub>)<sub>k</sub>-phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OR<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> alkyl and C<sub>1-4</sub>haloalkyl, and (4) C<sub>3-6</sub> cycloalkyl, or R<sup>b</sup> and R<sup>c</sup> together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered ring optionally containing an additional heteroatom selected from NR<sup>e</sup>, O, S, S(O) and S(O)<sub>2</sub>;
- R<sup>d</sup> is selected from (1) C<sub>1-4</sub> alkyl, (2) C<sub>1-4</sub>haloalkyl, (3) C<sub>1-4</sub> alkyloxy, (4) (CH<sub>2</sub>)<sub>k</sub>-phenyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OR<sup>a</sup>, CO<sub>2</sub>R<sup>a</sup>, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> alkyl and C<sub>1-4</sub>haloalkyl, (5) pyridyl, and (6) pyridyl N-oxide;
- R<sup>e</sup> is selected from hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C(O)H and C(O)C<sub>1-4</sub>alkyl;
- n is 1, 2, or 3;
- k is 0, 1, 2, 3, or 4; and
- v is 0, 1, or 2.

2. A compound of Claim 1 wherein R<sup>2a</sup>, R<sup>2b</sup> and the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted with 1 to 4 groups independently selected from halogen, OR<sup>a</sup>, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> haloalkyl.

5 3. A compound of Claim 1 wherein R<sup>1</sup> is




wherein R<sup>6</sup>, R<sup>8</sup> and R<sup>9</sup> are as defined in Claim 1.

10 4. A compound of Claim 3 wherein R<sup>6</sup> is selected from (1) -CO<sub>2</sub>-C<sub>1-4</sub>alkyl, (2) C<sub>1-4</sub>alkoxy, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C<sub>1-4</sub>alkyl group.

15 5. A compound of Claim 4 wherein R<sup>8</sup> is hydrogen or 3-halo, and R<sup>9</sup> is hydrogen or 5-halo.


6. A compound of Claim 1 wherein R<sup>1</sup> is



wherein R<sup>4a</sup>, R<sup>4b</sup> and R<sup>a</sup> are as defined in Claim 1.

7. A compound of Claim 6 wherein R<sup>4a</sup> and R<sup>4b</sup> are each fluoro.


25 8. A compound of Claim 1 having the formula (Ia) and pharmaceutically acceptable salts thereof:



wherein m is 1 to 5; Y is N or CH; one of R<sup>3a</sup> and R<sup>3b</sup> is hydrogen and the other is hydrogen or methyl;  
 5 R<sup>7</sup> is hydrogen or fluorine; R<sup>6</sup> is selected from (1) -CO<sub>2</sub>-C<sub>1-4</sub>alkyl, (2) C<sub>1-4</sub>alkoxy optionally substituted with 1 to 5 halogen atoms, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a C<sub>1-4</sub>alkyl group; and R<sup>8</sup> and R<sup>9</sup> are independently hydrogen or halogen.

10

9. A compound of Claim 1 having the formula Ib and pharmaceutically acceptable salts thereof:



15


where R<sup>3a</sup>, R<sup>3b</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are as defined in Claim 1, and R<sup>2a'</sup> and R<sup>2b'</sup> are independently selected from (1) hydrogen, (2) C<sub>1-7</sub> alkyl optionally substituted with 1 to 5 halogen atoms, SH, OH, S-C<sub>1-4</sub>alkyl or OC<sub>1-4</sub>alkyl, (3) (CH<sub>2</sub>)<sub>k</sub>-phenyl optionally substituted with 1 to 3 groups independently  
 20 selected from halogen, cyano, nitro, OH, C<sub>1-4</sub> alkyloxy, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> alkyl and C<sub>1-4</sub>haloalkyl, (4) C<sub>3-6</sub> cycloalkyl, (5) (CH<sub>2</sub>)<sub>k</sub>-pyridyl, and (6) (CH<sub>2</sub>)<sub>k</sub>-indolyl.

10. A compound of Claim 9 wherein R<sup>2a'</sup> and R<sup>2b'</sup> are independently C<sub>1-7</sub>alkyl optionally substituted with 1 to 5 halogen atoms.

25

11. A compound of Claim 10 wherein one of  $R^{3a}$  and  $R^{3b}$  is hydrogen and the other is hydrogen or methyl;  $R^7$  is hydrogen, chlorine or fluorine;  $R^6$  is selected from (1)  $-\text{CO}_2\text{-C}_{1-4}\text{alkyl}$ , (2)  $\text{C}_{1-4}\text{alkoxy}$  optionally substituted with 1 to 5 halogen atoms, and (3) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a  $\text{C}_{1-4}\text{alkyl}$  group; and  $R^8$  and  $R^9$  are independently hydrogen or halogen.

12. A compound of Claim 1 having the formula Ic and pharmaceutically acceptable salts thereof:



wherein Y is N or CH;  $R^7$  is H, chlorine or fluorine;  $R^{3a}$  is H or methyl;  $R^6$  is selected from (1)  $-\text{CO}_2\text{-C}_{1-4}\text{alkyl}$ , (2)  $\text{C}_{1-4}\text{alkoxy}$ , (3)  $\text{C}_{1-4}\text{haloalkyloxy}$ , and (4) a 5-membered heteroaromatic ring having a ring heteroatom selected from N, O and S, and optionally having up to 3 additional ring nitrogen atoms, said ring being optionally substituted with a  $\text{C}_{1-4}\text{alkyl}$  group; and  $R^8$  and  $R^9$  are independently hydrogen or halogen.

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

14. A method for the treatment or prevention of a condition mediated by bradykinin B1 receptor in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of Claim 1.

15. A method for the treatment or prevention of pain in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of Claim 1.

16. A method for the treatment or prevention of pain selected from acute pain, inflammatory pain and neuropathic pain in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of Claim 1.

5 17. Use of a compound of Claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of diseases or conditions mediated by bradykinin B1 receptor.

10 18. Use of Claim 17 wherein said diseases or conditions are acute pain, inflammatory pain and neuropathic pain.